Daily Cosmetic Research Analysis
Analyzed 6 papers and selected 3 impactful papers.
Summary
Analyzed 6 papers and selected 3 impactful articles.
Selected Articles
1. Kukui nut oil (Aleurites moluccanus seed oil) promotes hair growth by activating the Nrf2/ARE-AKR1C family-PGF2α signaling axis.
This paper identifies a mechanistic pathway by which Kukui (AMS) oil promotes hair growth: AMS oil activates Nrf2 signaling, upregulates AKR1C enzymes, increases PGF2α, and stimulates proliferation markers in human hair follicles; a randomized double-blind left-right human test confirmed eyelash growth efficacy.
Impact: Provides both mechanistic insight (Nrf2→AKR1C→PGF2α) and human efficacy data, bridging basic biology with a clinically testable cosmetic intervention.
Clinical Implications: Supports development of AMS oil–based topical therapeutics/cosmetics for hair and eyelash growth; justifies larger controlled clinical trials assessing safety, dose, and long-term effects.
Key Findings
- AMS oil increases PGF2α levels and upregulates AKR1C family enzymes in human hair follicles.
- AMS oil activates Nrf2 signaling leading to transcriptional regulation via antioxidant response elements.
- Randomized double-blind left-right human testing showed AMS oil promotes eyelash growth.
Methodological Strengths
- Combination of ex vivo human hair follicle experiments, transcriptional analysis, and human randomized double-blind left-right testing.
- Identification of a specific biochemical axis (Nrf2→AKR1C→PGF2α) with multiple supporting assays (biochemical, gene expression, proliferation markers).
Limitations
- Human randomized test was a left-right comparison; full-scale randomized parallel-group trials with larger and more diverse populations are lacking.
- Long-term safety, systemic absorption, and dose–response relationships were not fully characterized.
Future Directions: Conduct larger randomized controlled trials with diverse populations, assess long-term safety and optimal formulations/dosages, and explore potential systemic antioxidant benefits.
Hair plays an essential role in protecting the eyes and skin, and hair loss can cause psychological distress. Kukui nut oil (Aleurites moluccanus seed (AMS) oil) has been traditionally used to promote hair growth. While it is now widely used as a cosmetic ingredient, its mechanism for promoting hair growth has remained unknown. In this study, we investigated the hair growth-promoting mechanism of AMS oil, primarily focusing on prostaglandin F2α (PGF2α) production. Ex vivo culture of human hair follicles treated with AMS oil demonstrated a significant hair-growth effect. AMS oil elevated PGF2α levels and increased the expression of AKR1C family members, which are key enzymes involved in PGF2α synthesis. In addition, proliferation markers, including Ki67 and cyclins B1, D1, and E1, were upregulated. Transcriptional analysis revealed that AMS oil activates Nrf2 signaling, which leads to AKR1C family gene regulation via antioxidant response elements. Furthermore, a randomized, double-blind, left-right comparison human testing confirmed the efficacy of AMS oil in promoting eyelash growth. These findings suggest that AMS oil holds promise for applications not only in promoting hair and eyelash growth but also in improving health through its antioxidant effects.
2. Three decades of hematoma prevention in outpatient plastic surgery: 44,133 consecutive cases and suggested protocol.
A single-center retrospective review of 44,133 outpatient cosmetic operations over 1995–2024 implemented a 5-step hematoma prevention protocol including TXA; overall hematoma rate was 0.46% and declined to 0.2% after protocol adoption. TXA use in facial procedures was associated with a 91% reduction in hematoma (0.74% vs 0.06%, p<0.0001).
Impact: Largest single-center series in outpatient aesthetic surgery showing marked reduction in a major complication (hematoma) with an actionable protocol including TXA, directly translatable to practice.
Clinical Implications: Adopting a standardized multimodal hematoma prevention protocol (including perioperative TXA) can substantially reduce reoperation-requiring hematomas in outpatient aesthetic procedures; supports guideline development and prospective validation.
Key Findings
- Across 44,133 consecutive outpatient cosmetic procedures, overall hematoma rate was 0.46% (203 events).
- After implementation of the 5-step protocol, hematoma rate declined to 0.2% during 2017–2024.
- In facial procedures, tranexamic acid use was associated with a 91% reduction in hematoma rates (0.74% vs. 0.06%; p<0.0001).
Methodological Strengths
- Extremely large sample size (44,133 consecutive cases) over three decades enhances generalizability within the center.
- Clear clinical endpoint (hematoma requiring reoperation within 30 days) and quantitative pre/post protocol comparisons with subgroup analysis for facial procedures.
Limitations
- Single-center retrospective design; potential for unmeasured temporal confounders and practice changes over three decades.
- Lack of randomized allocation to TXA and limited detail on dosing regimens, selection criteria for TXA, and adverse event surveillance.
Future Directions: Prospective multicenter trials or registry-based studies to validate the protocol and optimize TXA dosing, timing, and patient selection; cost-effectiveness analyses.
Hematoma prevention in outpatient plastic surgery is crucial for patient safety and procedural success. This study evaluates hematoma rates over three decades of outpatient cosmetic procedures and outlines a structured multimodal prevention protocol. We conducted a single-center, retrospective review of 44,133 consecutive cosmetic procedures performed by board-certified plastic surgeons between 1995 and 2024 at an accredited outpatient surgical facility with postoperative nursing observation capabilities. A structured 5-Step Hematoma Prevention Protocol, incorporating tranexamic acid (TXA), was implemented. Hematoma was defined as a postoperative blood collection requiring reoperation within 30 days. Overall, 203 hematomas occurred, yielding a rate of 0.46%. Following adoption of the protocol, the hematoma rate declined to 0.2% during 2017-2024. In facial procedures, TXA use was associated with a 91% reduction in hematoma rates (0.74% vs. 0.06%; p<0.0001). To our knowledge, this represents the largest single-center analysis of outpatient hematoma prevention, spanning three decades and over 44,000 cases. This analysis supports the role of a structured multimodal protocol-with TXA as a key component-in minimizing hematoma risk. Broader adoption of standardized strategies may enhance patient safety and optimize outcomes in aesthetic surgery.
3. Thyroid Artery Embolization for Benign Symptomatic Multinodular Euthyroid Goiter: 24-Month Outcomes from a Single- Center Retrospective Study.
Single-center retrospective study of 40 consecutive patients (mean follow-up ~30 months) undergoing thyroid artery embolization for benign multinodular euthyroid goiter. Total thyroid volume decreased by ~53% at 12 months and ~60% at 24 months; dominant nodule volume decreased by ~53% and ~68% respectively. Symptom resolution exceeded 95% and reintervention was required in 7.5%; overall complication rate 35% with major complications 5%.
Impact: Demonstrates durable volumetric and symptomatic benefit of a minimally invasive TAE approach with 24-month follow-up, offering a surgical alternative for symptomatic patients who are euthyroid and prefer non-surgical management.
Clinical Implications: TAE may be considered an effective minimally invasive option for symptomatic multinodular euthyroid goiter in patients unsuitable for or unwilling to undergo surgery; however, risk of transient hyperthyroidism and rare major complications requires careful patient selection and monitoring.
Key Findings
- Mean total thyroid volume decreased by 53.31% at 12 months and 60.14% at 24 months (p < .001).
- Mean dominant nodule volume decreased by 53.33% at 12 months and 68.05% at 24 months (p < .001).
- Symptom resolution occurred in 95.0% at 12 months and 97.5% at 24 months; reintervention rate 7.5%; overall complication rate 35% (major complications 5%).
Methodological Strengths
- Consecutive case inclusion with median ~30 months follow-up provides mid-term effectiveness data.
- Clear volumetric primary endpoints with statistical significance at 12 and 24 months and subgroup analysis by goiter location.
Limitations
- Small sample size (n=40) and single-center retrospective design limit generalizability.
- High overall complication rate (35%) and presence of rare major events (cerebellar infarction) warrant cautious interpretation; no control or comparison to surgical outcomes presented.
Future Directions: Larger multicenter prospective studies comparing TAE to surgical and other nonsurgical options, with standardized reporting of complications, thyroid function, and quality-of-life outcomes.
PURPOSE: To evaluate the effectiveness of thyroid artery embolization (TAE) in patients with benign symptomatic multinodular euthyroid goiter. MATERIALS AND METHODS: This retrospective single-center observational study included consecutive patients treated between December 2021 and June 2024. Forty patients were analyzed with a mean follow-up of 29.85 ± 12.38 months. Primary endpoints were percent changes in total thyroid volume and dominant nodule volume at 12 and 24 months. Secondary endpoints included symptom and cosmetic improvement, recurrence, reintervention, and complications. RESULTS: Mean total thyroid volume decreased from 118.45 ± 36.60 mL at baseline to 54.78 ± 20.15 mL at 12 months and 46.73 ± 15.70 mL at 24 months (both p < .001), corresponding to reductions of 53.31% ± 12.81% and 60.14% ± 11.12%, respectively. Mean dominant nodule volume decreased from 31.60 ± 11.69 mL to 14.59 ± 7.12 mL at 12 months and 10.08 ± 4.35 mL at 24 months (both p < .001), representing reductions of 53.33% ± 16.94% and 68.05% ± 11.49%. Symptom resolution occurred in 95.0% of patients at 12 months and 97.5% at 24 months. Recurrence was observed in 1 patient (2.5%), and reintervention was required in 3 patients (7.5 %). Volumetric outcomes were similar between cervical and substernal goiters (all p > .05). The total complication rate was 35%, most commonly transient hyperthyroidism (22.5%); the major complication rate was 5%, comprising one cerebellar infarction and one perithyroidal hematoma requiring percutaneous drainage. CONCLUSIONS: TAE resulted in substantial and sustained volume reduction with high rates of clinical improvement and low mid-term reintervention rates.